Multivalent Pan-Influenza Vaccine Antigen Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current influenza vaccines have limited efficacy and durability, failing to provide broad protection against various strains, leading to significant morbidity and mortality, especially among the elderly, due to rapid waning of immunity and antigenic drift.
Innovation Solution
Development of multivalent pan-influenza vaccines comprising viral haemagglutinin (HA) proteins or HA1-containing portions from distinct virus strain groups, including H1-CVG1 to H1-CVG4, H3-CVG1 to H3-CVG4, and Influenza B-CVG1 and B-CVG2, which are formulated to elicit a robust immune response across multiple antigenic sites, including N-linked glycosylation sites, and can be administered as inactivated or recombinant components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current seasonal influenza vaccines are used, then vaccination campaigns can be implemented, but vaccine efficacy is limited and wanes rapidly
Solution Approach 1:
The vaccine divides the influenza virus into distinct antigenic components by selecting representative strains from different component virus groups (H1-CVG-1 to H1-CVG-4, H3-CVG-1 to H3-CVG-4, Influenza B-CVG-1 and B-CVG-2). Each segment represents a specific antigenic cluster, allowing the immune system to recognize and respond to multiple viral variants simultaneously, thereby extending the duration of protective immunity.
Solution Approach 2:
The multivalent vaccine formulation provides universal protection by incorporating antigens from multiple influenza A and B strain groups into a single vaccine product. This multi-functional approach enables the vaccine to protect against both homologous and heterologous strains, addressing the limitation of single-strain vaccines that rapidly become ineffective due to antigenic drift.
2Adaptability or versatility
If single-strain influenza vaccines are used, then manufacturing is simpler, but protection against heterologous strains is insufficient
Solution Approach 1:
The vaccine composition is segmented into distinct antigenic components, with each component representing a specific influenza strain group. This segmentation allows for targeted immunization against multiple strain groups while maintaining a structured and manageable formulation approach, balancing complexity with enhanced protective breadth.
Solution Approach 2:
The multivalent vaccine achieves universality by integrating multiple influenza A and B strain groups into a single formulation. This approach provides broad protection against both homologous and heterologous strains, overcoming the limitation of single-strain vaccines without requiring multiple separate vaccination campaigns.
3Reliability
If vaccines are updated annually to match circulating strains, then current strain protection is optimized, but immunity against emerging strains is not maintained
Solution Approach 1:
The vaccine segments the influenza virus into distinct antigenic groups (H1-CVG-1 to H1-CVG-4, H3-CVG-1 to H3-CVG-4, Influenza B-CVG-1 and B-CVG-2), allowing the immune system to maintain recognition of multiple strain groups simultaneously. This segmentation enables both current strain protection and cross-protection against emerging variants.
Solution Approach 2:
The multivalent vaccine performs preliminary immunization by pre-exposing the immune system to multiple influenza strain groups before infection occurs. This preliminary action builds a comprehensive immune repertoire that includes both current and emerging strain recognition, eliminating the need for annual vaccine updates to maintain cross-strain protection.
Data Source
AI summary
Provided are highly immunogenic multivalent pan-influenza vaccines, comprising a viral haemagglutinin (HA) protein, or HA1-containing portion thereof, of/corresponding to a virus strain from each of any three of, or from all four of component virus strain groups (H1-CVG1-H1-CVG-4) as defined herein. Additionally provided are highly immunogenic multivalent pan-influenza vaccine, comprising a viral hacmagglutinin (HA) protein, or HA1-containing portion thereof, of/corresponding to a virus strain from each of any three of, or from all four of component virus strain groups (H3-CVG-1-H3-CVG-4) as defined herein. Further provided are highly immunogenic multivalent pan-influenza vaccine, comprising a viral haemagglutinin (HA) protein, or HA1-containing portion thereof, of/corresponding to a virus strain from each of two component virus strain groups Influenza B-CVG-1 and Influenza B-CVG-2 as defined herein. Yet further provided are methods for making the immunogenic vaccine compositions, and methods for eliciting an immune response, comprising administering the immunogenic vaccine compositions.